Azelastine Nasal Spray May Lower COVID-19 Infection Risk: JAMA Dr. Shravani Dali16 Sept 2025 2:45 PMResearchers have found in a new study that azelastine nasal spray may help reduce the risk of SARS-CoV-2 infection. Azelastine, a second-generation...
Seizures among children swallowing medications or illegal substances doubled over 15-year period: Study Dr. Kamal Kant Kohli1 Nov 2024 3:15 PMCopenhagen: New data shows that the number of children suffering a seizure after swallowing medications or illegal substances has doubled between 2009...
Allergic Rhinitis and ENT Practice: Review and Evidence Emphasis on Fluticasone Furoate Dr. Kamal Kant Kohli11 July 2024 6:30 AMAllergic rhinitis (AR) affects approximately 25% and 40% of children and adults globally, respectively. In 80% of the cases, the symptoms occur before...
No benefit of adjuvant leukotriene receptor antagonists with antihistamines in chronic urticaria: Study Medha Baranwal8 May 2024 2:30 PMBrazil: A comprehensive systematic review and meta-analysis have shed new light on the potential of leukotriene receptor antagonists (LTAs) as...
Intranasal Medications Show Efficacy in Treating Allergic Rhinitis: Study Dr Riya Dave3 May 2024 2:30 AMResearchers have found that most intranasal medications, including corticosteroids and antihistamines, are effective in improving nasal and ocular...
Allergic Rhinitis: Challenges, Treatment Choices and Clinical Spotlight on Fexofenadine Dr. Kamal Kant Kohli1 April 2024 5:00 AMAllergic rhinitis (AR) is a common inflammatory disease affecting the nasal mucosa, induced by inhaled allergens. It is clinically manifested by...
Allergic Rhinitis Aggravated by Air Pollutants: Review of International Expert Consensus and Clinical Essay on Fexofenadine Dr. Kamal Kant Kohli16 March 2024 7:13 AMAllergic rhinitis (AR) has become a progressively prevalent inflammatory condition affecting the nasal mucosa, often stemming from exposure to inhaled...
Require additional efficacy data for Dupixent approval for chronic spontaneous urticaria: USFDA to Sanofi Ruchika Sharma23 Oct 2023 11:14 AMDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Vestibular suppressants don't alleviate symptoms in Benign Paroxysmal Positional Vertigo Dr. Kamal Kant Kohli15 Nov 2022 2:30 PMU.S.A: According to research reported in Academic Emergency Medicine, vestibular suppressants may not have any effect on symptom resolution in Benign...
Improvement in quality of Life after management of Allergic Rhinitis Dr. Nandita Mohan4 Aug 2022 5:30 AMAllergic rhinitis (AR) is associated with disturbed sleep and subsequent functioning, and an impaired quality of life (QoL). The symptoms of...
Antihistamines superior to benzodiazepines in the treatment of acute vertigo: JAMA Jacinthlyn Sylvia20 July 2022 6:30 AMUSA: Acute vertigo is a distressing and disabling condition. Antihistamines and benzodiazepines are frequently prescribed as "vestibular...
Antihistamines show promise in treating long COVID-19 symptoms, UCI case report says Hina Zahid16 Feb 2022 3:30 AMIrvine, Calif. - Antihistamines may provide relief for the millions of people suffering from the painful, debilitating symptoms of long COVID-19...
